Quantcast

Drug Manufacturer Watson Sues FDA Over Generic Actos Release

Watson Pharmaceuticals has filed a lawsuit against the FDA for denying shared exclusivity, despite the fact that the drug company followed all the FDA’s requirements. Watson planned to release the generic version of Takeda Pharmaceutical’s controversial Actos drug on August 17th. In 2010, Watson got approval to market the generic pioglitazone … [Read more...]

Actos Increases Bladder Cancer Risk Compared to Different Class of Diabetes Drugs

A new study released earlier this month, and published in the Journal of the National Cancer Institute, found that thiazolidinedione (TZD) drugs like Actos were more likely to cause bladder cancer than a different class of drugs called sulfonylurea drugs. Patients who took TZD drugs were two to three times more likely to develop bladder cancer than … [Read more...]

Actos Bellwether Cases Scheduled for MDL 2299

Presiding Judge Rebecca Doherty has issued a detailed schedule for proceedings in the Actos Multidistrict Litigation (MDL) 2299. Bellwether trials, which are typical in MDLs, are early trials designed by both parties to gauge the juries’ reactions to evidence. The trials picked as bellwether cases normally represent egregious cases. Attorneys … [Read more...]

Actos Lawsuit

The Strom Law Firm is now accepting product liability and personal injury cases regarding the use of Actos and its link to bladder cancer.  Call us right now for a free case review to see if we can help you. 803.252.4800 Actos drug maker Takeda Pharmaceutical Co. Ltd. was hit in California yesterday with what is expected to be the first of … [Read more...]

Women with Type 2 Diabetes More Likely to Develop, Less Likely to Survive, Breast Cancer

Two studies published recently report on the link between Type 2 diabetes and breast cancer. One study led by A.L. Ronco of Pereira Rossell Women's Hospital in Montevideo, Uruguay, showed that women who were obese and had Type 2 diabetes related to obesity were 9 times as likely to develop breast cancer. The other study, led by Wei-Wu Chen of … [Read more...]

Women At Greater Risk of Developing Type 2 Diabetes

A recent study of diabetes and job stress showed that women who were micromanaged were at greater risk of developing Type 2 diabetes than their male counterparts. However, job stress is not the only thing that increases professional women’s risk of diabetes. Peter Smith, lead author of the nine-year study by researchers at the Institute for Work … [Read more...]

10,000 Lawsuits: Actos Injury Filing in Multidistrict Litigation 2299 Streamlined

Judge Rebecca Doherty signed a Direct Filing Order in April that allows any plaintiff to add their lawsuit directly to Actos Multidistrict Litigation 2299. In December 2011, a federal Judicial Panel consolidated several Actos lawsuits under one federal court, in Lafayette, Louisiana. The Honorable Rebecca Doherty is presiding over the … [Read more...]

FDA Rejects Actos-Based Drug for the 2nd Time

In April of this year, the FDA rejected Takeda Pharmaceuticals’ Actos style new drug, called alogliptin, citing a lack of data regarding the drug’s side effects. Takeda Pharmaceuticals has been under fire in the last two years from patients who claim their drugs, specifically Avandia and Actos, cause severe side effects, and that Takeda knew about … [Read more...]

Weight Loss Surgery Reduces Risk of Type 2 Diabetes, Good News for South Carolina

A Swedish study that followed more than 3,400 obese men and women shows that bariatric surgery, more than lifestyle changes and medication, reduces the risk of diabetes by up to 78%. Bariatric surgery shrinks the stomach, so it holds less food and absorbs fewer calories. The surgery is normally recommended as a last resort for obese patients. … [Read more...]

Skip Generic Actos, for Health and Legal Reasons

Earlier this month, despite numerous lawsuits against Takeda Pharmaceuticals Actos, the FDA approved pioglitazone – the generic name for Actos – for market in the United States. Now, watchdog group Consumer Reports says the “bargain” should be avoided. For one thing, Consumer Reports points out, the generic version will not currently save patients … [Read more...]

BestLawyers.comAVBetter Business Bureau